Guardant resolves lllumina litigation, will share cancer research specimens
Georgejason/iStock Editorial via Getty Images
Guardant Health (NASDAQ:GH) said it has entered into an agreement with Illumina (NASDAQ:ILMN) that resolves their pending litigation and extends their commercial relationship.
Under the agreement, the companies will ask the court to dismiss their pending litigation with prejudice, including claims related to intellectual property. The companies have also agreed to a long-term supply and purchase commitment and to share specimens for cancer research.
Guardant, a developer and marketer of cancer detection products, didn't provide any additional details about the agreement. 
Last month, Illumina CEO Francis de Souza resigned following a board battle with activist investor Carl Icahn. The company was also fined $475M by EU authorities for merging with cancer screening company GRAIL without first obtaining regulatory approval. 
In an unusual move, the FTC in April ordered Illumina to divest GRAIL, citing concerns that it would thwart competition in the cancer detection market. Illumina is appealing the ruling. 
More on Illumina and Guardant:
Hologic CEO Steve MacMillan says he's not leaving after taking on Illumina chair role
Illumina fined $475M in EU for closing GRAIL acquisition
Illumina, Inc.: Collapsing Margins, Rising Debt, Legal Setbacks, And Downward Momentum
Guardant Health: A Growth Company Expanding Its Product Line Quickly